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Abstract: The cAMP analogue 8-Br-cAMP-AM (8-Br) confers marked protection against global
ischaemia/reperfusion of isolated perfused heart. We tested the hypothesis that 8-Br is also protective
under clinically relevant conditions (regional ischaemia) when applied either before ischemia or at the
beginning of reperfusion, and this effect is associated with the mitochondrial permeability transition
pore (MPTP). 8-Br (10 µM) was administered to Langendorff-perfused rat hearts for 5 min either
before or at the end of 30 min regional ischaemia. Ca2+-induced mitochondria swelling (a measure
of MPTP opening) and binding of hexokinase II (HKII) to mitochondria were assessed following
the drug treatment at preischaemia. Haemodynamic function and ventricular arrhythmias were
monitored during ischaemia and 2 h reperfusion. Infarct size was evaluated at the end of reperfusion.
8-Br administered before ischaemia attenuated ventricular arrhythmias, improved haemodynamic
function, and reduced infarct size during ischaemia/reperfusion. Application of 8-Br at the end of
ischaemia protected the heart during reperfusion. 8-Br promoted binding of HKII to the mitochondria
and reduced Ca2+-induced mitochondria swelling. Thus, 8-Br protects the heart when administered
before regional ischaemia or at the beginning of reperfusion. This effect is associated with inhibition
of MPTP via binding of HKII to mitochondria, which may underlie the protective mechanism.
Keywords: cyclic AMP; heart; regional ischaemia; cardioprotection; reperfusion injury; mitochondria
permeability transition pore; hexokinase II
1. Introduction
Acute myocardial infarction (AMI) remains the most significant cause of death and
disability worldwide [1]. It is commonly accepted that the only effective treatment of AMI
is reperfusion of the ischaemic area, which can be attained by thrombolysis, percutaneous
coronary intervention, or coronary artery bypass grafting [2–4]. Unfortunately, reperfusion
injury can cause necrosis and apoptosis of the affected myocardium [5]. Reperfusion injury
is associated with the opening of the mitochondria permeability transition pore (MPTP)
which can be caused by elevated concentrations of Ca2+ [6] and reactive oxygen species
(ROS) [7,8]. Currently, there are no effective interventions that can reduce the size of the
infarction or attenuate remodelling towards heart failure.
We and others have shown that the cyclic AMP (cAMP) signalling pathways are
cardioprotective under different conditions [9–11]. A major problem associated with
these interventions, however, is their reliance on of β-adrenergic receptors (βARs). The
sensitivity of these receptors could be blunted in chronic heart failure or hypertension due
to βAR hyperstimulation mediated by the sympathoadrenal system [12,13]. Therefore,
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direct activation of the protective cAMP signalling that does not involve βAR stimulation
would overcome this problem. cAMP activates two major signal transduction pathways
in the heart, PKA [14] and a guanine nucleotide exchange protein directly activated by
cAMP (Epac) [15]. We recently found that a brief (5 min) perfusion of hearts with the
non-selective cell-permeable cAMP analogue 8-Br-cAMP-AM (8-Br) at the concentration of
10 µM can induce a potent cardioprotective effect [16]. However, experiments in that study
were performed on hearts exposed to global ischaemia/reperfusion (I/R). Also, the cAMP
analogues in that study were applied only before ischaemia. The clinical applicability of this
kind of treatment is limited to cardiac surgery involving aortic cross-clamping that causes
global ischaemia. Meanwhile, the aetiology of AMI is mostly associated with regional
ischaemia caused by occlusion of a coronary artery [17]. Furthermore, the treatment prior
to the ischemic event is impossible in most cases because an incident of AMI cannot be
predicted. Therefore, a drug is needed that can protect the heart against regional I/R
and when applied at the onset of reperfusion (recanalization of the coronary artery). In
this work, we studied the cardioprotective potential of 8-Br when administered before
regional ischaemia or at the start of reperfusion following regional ischaemia. Since MPTP
opening triggered by high levels of Ca2+ and ROS is the critical mechanism of reperfusion
injury [18], we investigated the effect of 8-Br on the sensitivity of MPTP to Ca2+ overload.
2. Materials and Methods
2.1. Materials
The non-selective cell-permeable cAMP analogue 8-bromoadenosine-3’,5’-cyclic mono
phosphate, acetoxymethyl ester (8-Br) was obtained from BioLog Life Science Institute
(Bremen, Germany). Other chemicals were acquired from Sigma (Gillingham, UK). General
consumables were bought from Fischer Scientific (Loughborough, UK) or VWR-Jencons
(Lutterworth, UK).
2.2. Animals
The experiments were carried out using two-month-old male Wistar rats (250–260 g)
obtained from Charles River Laboratories (Oxford, UK). Before experiments, the rats were
housed at the University of Bristol Animal Services Unit for 2–4 days at the standard
conditions: air temperature of 23 ± 1 ◦C, relative humidity of 60–70%, light/dark cycle
of 12 h, and free access to standard rat chow and water. The rats were kept in standard
cages with aspen bedding. Two to three animals were present in a cage. The animals
were sacrificed by stunning and cervical dislocation and the hearts were extracted for
Langendorff perfusion.
2.3. Langendorff Perfusion of Isolated Rat Heart
Rats were killed as described above. Hearts (~0.75 g) were immersed in ice-cold Krebs–
Henseleit buffer (KH) containing (mM): 118 NaCl, 25 NaHCO3, 4.8 KCl, 1.2 KH2PO4,
1.2 MgSO4, 11 glucose, and 1.2 CaCl2, gassed with 95% O2–5% CO2 at 37 ◦C (pH 7.4) and
perfused by Langendorff as described previously [19]. The equilibration period lasted for
30 min before the treatment. Acquisition of the data followed by the data analysis was
performed using a PowerLab System (ADInstruments Ltd., Oxford, UK). The following
parameters were calculated: left ventricular developed pressure (LVDP) was computed
as the difference between left ventricular systolic pressure (LVSP) and left ventricular
end-diastolic pressure (LVEDP); rate-pressure product (RPP) was calculated as the product
of LVDP and heart rate (HR); time derivatives of pressure during contraction (+dP/dt) and
relaxation (−dP/dt) were calculated by Chart 5 software (ADInstruments Ltd., Oxford,
UK). Preischaemic values of the parameters of haemodynamic function were assessed at
the end of the equilibration period before a preischaemic treatment. Since the perfused
hearts beat spontaneously, haemodynamic function depended on both LVDP and HR.
Therefore, RPP was used as the main parameter of haemodynamic function. The hearts
with an RPP less than 15,000 mmHg·beat·min−1 at the end of the equilibration period
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were withdrawn from the experiment. For analysis of the dynamics of RPP and LVDP
during regional ischaemia and reperfusion, the results were presented as a percentage of
pre-treatment value. This normalization was carried out to avoid significant variations in
the absolute values.
2.4. Heart Perfusion Protocols
The experimental protocols are shown in Figure 1. After a 40 min preischaemic period,
hearts were subjected to 30 min regional normothermic ischaemia (37 ◦C) followed by 2 h
reperfusion. Regional ischaemia was induced by occlusion of the left anterior descending
coronary artery (LAD) [20]. Briefly, a 5/0 braided silk thread was placed around the LAD.
The ligature was positioned at the starting quarter of LAD. Reperfusion was induced by
the release of the thread around the LAD.
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Figure 1. Experimental protocol. Upper panel—a schematic representation of the regional ischaemia
induced by the LAD occlusion. Lower panel—protocols of heart perfusion and ventricular sample
collection. 8-Br was perfused for 5 min at the concentration of 10 µM followed by a 5 min washout
period. Hearts of C-Mito and 8-Br-Mito groups (n = 5 and 7, respectively) were not subjected to
ischaemia and used for isolation of mitochondria. C-Pre and C-Post—control groups of hearts for the
First and Second series of experiments (n = 7 and 6, respectively). 8-Br-Pre and 8-Br-Post—groups of
hearts treated with 8-Br either before regional ischaemia (first series of experiments) or at the end of
30 min regional ischaemia (second series of experiments).
Hearts were randomly assigned to control (C) or intervention (8-Br) groups. In the
first intervention group, 8-Br (10 µM) was administered for 5 min, followed by 5 min
washout before regional ischaemia and reperfusion (8-Br-Pre group, n = 5). In the second
intervention group, 5 min heart perfusion with 10 µM 8-Br and 5 min washout were carried
out at the end of regional ischaemia (8-Br-Post group, n = 7). Hearts of control groups
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(C-Pre, n = 7, and C-Post, n = 6) were not subjected to any pharmacological intervention.
At the end of the experimental protocol, hearts were used for quantification of the infarct
size. Other hearts for control (C-Mito, n = 5) and interventions (8-Br-Mito, n = 7) were used
for the determination of hexokinase II (HKII) binding to mitochondria and Ca2+-induced
mitochondria swelling.
2.5. Analysis of the Left Ventricular Arrhythmias
Electrocardiogram (ECG) was recorded over the duration of the experiment by placing
two 0.1 mm in diameter silver wire electrodes on the heart apex and right atrium. The
ground electrode of the ECG was attached to the base of the aorta. The electrodes were
connected to a bio amplifier of a PowerLab System. The ventricular arrhythmias were
analysed for the duration of the LAD occlusion and the first 30 min of reperfusion according
to the Lambeth Conventions [21]. The incidences of the following types of arrhythmias
were assessed: ventricular premature beats (VPBs), ventricular tachycardia (VT—four or
more consecutive VPBs), and ventricular fibrillation (VF—irregular deflections of QRS).
Bigeminy and salvos (VPB doublet or triplet) were included in the analysis of VPBs. We
used the scoring system of Curtis and Walker (1988) [22] with modifications to quantify
arrhythmias. The following characteristics of the scoring system were adopted: 0, no
arrhythmia; 1, 1–100 VPBs; 2, >100 VPBs; 3, <three episodes of VF/VT; 4, 3–10 episodes of
VF/VT; and 5, >10 episodes of VF/VT. After 30 min reperfusion, ECG was largely restored
and no malignant arrhythmias were observed at this stage of the experiment.
2.6. Infarct Size
The infarct size measurements were carried out at the end of reperfusion largely
as described previously with modifications [23]. Specifically, after 2 h reperfusion, the
hearts were injected with 20 mL of phosphate-buffered saline (PBS) (w/v, pH 7.4, 37 ◦C)
containing 1% triphenyl tetrazolium chloride through a sidearm of the aortic cannula at
the rate of 10 mL/min. Then, the LAD occlusion was reinstated, and 0.1% Evans blue
dissolved in KH (w/v, pH 7.4, 37 ◦C) was injected at the rate of 0.5 mL/min for 6 min using
a syringe pump via a sidearm of the aortic cannula. Then, the hearts were withdrawn from
the perfusion system and kept in a freezer at −20 ◦C for 50–60 min. The frozen hearts were
cut into 6 slices and left overnight at 4 ◦C in 4% formaldehyde solution in PBS. The next
day, the heart slices were scanned by an HP scanner. The area at risk (AAR), not stained
with Evans blue, and the area of infarct (IS), the white pale zone inside the area at risk
(Figure 2), were measured at both sides of each slice using an AlphaEase v5.5 software.
The ratio of the total IS to the total AAR of the heart (IS/AAR) was calculated.
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2.7. Ca2+-Induced Mitochondria Swelling Assay
Fast isolation of mitochondria was carried out as we have done previously [24]. All
the procedure was performed on ice or at 4 ◦C. Ventricles were rapidly cut away at the
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end of preischaemic period, homogenised using a Polytron homogenizer (Kinematica)
at 10,000 rpm (two bursts of 5 s followed by one burst of 10 s) in 6 mL of the ISA buffer
containing: sucrose 300 mmol/L, EGTA 1 mmol/L, and Tris-HCl 10 mmol/L, pH 7.2. ISA
containing 5 mg/mL bovine serum albumin (BSA) was added to the homogenate to the
total volume of 30 mL, and the suspension was additionally homogenised for 2 min in a
50 mL glass Potter homogenizer with a Teflon pestle. The homogenate was centrifuged at
2000× g for 90 s to remove cell debris (the pellet). The supernatant was then centrifuged at
10,000× g for 5 min. The pellet was resuspended in 1 mL of ISA, without EGTA and BSA,
and centrifuged at 10,000× g for 5 min. The resultant supernatant was poured out and the
pellet (the crude mitochondria) were resuspended in 200 µL of the same buffer.
2.8. Evaluation of Mitochondria-Bound Hexokinase II (HKII)
Mitochondria were isolated as we have done previously [25,26]. This method al-
lows acquiring pure mitochondria, free from other membranes [25]. In brief, the hearts
withdrawn at the end of the preischaemic period were homogenised in ISA buffer using
a Polytron and then in ISA buffer containing 5 mg/mL BSA as explained above. The
homogenate was centrifuged at 2000× g for 90 s and the cell debris was discarded. The su-
pernatant was then centrifuged at 10,000× g for 5 min, the pellet was resuspended in 30 mL
of ISAPP buffer (ISA supplemented with complete protease inhibitors cocktail (Roche) and
phosphatases inhibitors cocktail 1 (Sigma)) and centrifuged at 10,000× g for 5 min to obtain
a mitochondrial pellet. The pellet was diluted to 6 mL with ISAPP containing 25% (w/v)
Percoll (pH 7.2) and centrifuged at 17,000× g for 10 min. The supernatant was carefully
pipetted out; the resulting pellet was resuspended in 6 mL of ISAPP and centrifuged again
at 7000× g for 10 min. The purified mitochondrial pellet was resuspended in 200 µL of
ISAPP and stored at −80 ◦C for later analysis of HKII expression.
2.9. Western Blots (Binding of Hexokinase II to Mitochondria)
For determination of HKII binding to mitochondria, frozen mitochondria samples
were thawed and the protein concentration was adjusted to a final concentration of
4 mg/mL using BCA protein assay (Fisher Scientific UK Ltd., Loughborough, UK). The
samples were diluted 1:1 (v/v) with the SDS sample buffer (50 mM Tris-HCl, 2 mM EDTA,
12% glycerol, 10% SDS, 5% (v/v) 2-mercaptoethanol, and 0.01% (w/v) bromophenol blue).
The proteins were separated by 10% SDS-PAGE and processed using Western blotting
with antibodies against HKII (Cell Signaling Technology Inc., NEB, Hitchin, UK; diluted
1:1000). Each blot carried samples from control and 8-Br groups of hearts (40 µg per lane).
Protein loading was validated using an anti-VDAC antibody (Cell Signaling Technology,
Inc.; diluted 1:1000). Western blots were developed using anti-rabbit Ig horseradish peroxi-
dase secondary antibo-Aldrichdy with ECL/ECL+ detection (Amersham Biosciences Ltd,
Little Chalfont, UK). The blots were quantified using a digital ChemiDoc imaging system
(Bio-Rad, Deeside, UK). AlphaEase v5.5 software was used to analyse band intensity. The
data were normalised for protein loading and background was subtracted.
2.10. Mitochondrial Permeability Transition Pore (MPTP) Opening
Several methods of measuring MPTP opening are available: Ca2+ retention capacity
using fluorescence-based analysis [27], [3H]DOG entrapment assay [28], measurements
of mitochondrial and cytosolic NAD+ [29], and others. We measured Ca2+-induced mito-
chondria swelling, which represents a well-established and commonly accepted method
of evaluation of MPTP opening in isolated mitochondria [30]. The MPTP opening was
measured in de-energised mitochondria at 30 ◦C using a double-beam spectrophotometer
as described previously [28]. The mitochondria swelling was assessed by a decrease in
light scattering (at the wavelength of 520 nm) observed after the addition of Ca2+ to the
suspension of mitochondria. The mitochondria suspension buffer (pH 7.2) contained (mM)
150 KSCN, 20 Mops, 10 Tris, 2 nitrilotriacetic acid, 2 µM A23187 (Sigma-Aldrich, Gilling-
ham, UK), 0.5 µM rotenone (Sigma-Aldrich) and 0.5 µM antimycin A (Sigma-Aldrich).
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Mitochondria isolated from hearts at the end of 40 min preischaemic period, with or
without 5 min perfusion with 8-Br (Figure 1), were diluted to 0.2 mg/mL. Protein concen-
tration was adjusted using a Biuret protein assay. CaCl2 was added at 3 mM. The resultant
buffered-free Ca2+ concentration was 300 µM.
2.11. Statistical Analysis
Data are presented as the mean ± SEM. The hearts were randomly distributed between
different groups. Statistically significant differences in haemodynamic function between the
groups were assessed by one-way ANOVA followed by Fisher’s LSD multiple comparison
post hoc test. Statistically significant differences of haemodynamic function of hearts
during perfusion with 8-Br vs. pre-treatment values, either before or at the end of regional
ischaemia, were evaluated using one-way ANOVA repeated measures followed by Fisher’s
LSD multiple comparison post hoc test. Statistically significant differences in arrhythmia
score, infarct size, and protein expression in Western blots were assessed using a two-tailed
unpaired Student’s t-test. The results were considered statistically significant at p < 0.05.
The post hoc tests were performed if the F-test of variance reached the necessary level of
statistical significance. SPSS Statistics software, Version 23 (IBM, Portsmouth, UK), was
used for the statistical analysis.
3. Results
3.1. The Effects of 8-Br Added before Ischemia
3.1.1. Changes in Haemodynamic Function
Heart perfusion with 10 µM 8-Br before the start of regional ischaemia (at the end of
preischaemia) resulted in a sharp increase in LVDP, up to 200 ± 18% of the pre-treatment
value at the end of the 5 min perfusion with the drug (Figure 3). The following 5 min
washout with KH reversed the changes in LVDP, and at the end of preischemic period, this
parameter fell below the pre-treatment value. HR was slightly but significantly increased
during the heart perfusion with 8-Br and the washout period. Accordingly, RPP rose
dramatically during the heart perfusion with 8-Br (up to 230 ± 27%). At the end of the
washout period, RPP fell well below the pre-treatment value (to 66 ± 9%; Figure 3).
3.1.2. Changes in Haemodynamic Function during Ischaemia and Reperfusion
In the first series of experiments, the occlusion of the LAD caused a similarly sharp
and immediate fall in the LVDP in both the control and 8-Br-Pre groups, to 68 ± 6% and
59 ± 4%, respectively (Figure 3). Then, this parameter started a gradual recovery. At the
end of regional ischaemia, LVDP reached 73 ± 9% in the C-Pre and 85 ± 7% in the 8-Br-Pre
groups. No significant difference was observed in LVDP between the two groups during
regional ischaemia.
During reperfusion, LVDP continued recovering in both groups. In the control group,
the increase in LVDP reached its peak (91 ± 9%) at the 40th min. From that point to the end
of reperfusion, this parameter did not change significantly. The increase in LVDP in the
8-Br-Pre group was faster and continued longer, until the 60th min of reperfusion, reaching
the peak of recovery of 122 ± 8% (p < 0.05 vs. control). Afterward, LVDP in 8-Br-Pre hearts
continued to be higher compared to the control (Figure 4).
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3.2.1. Changes in the Haemodynamic Function during 8-Br Treatment
At the onset of reperfusion (at the end of regional ischaemia), heart perfusion with
10 µM 8-Br brought about a fast increase in LVDP, reaching 247 ± 18% of the pre-treatment
value at the end of the 5 min perfusion with the drug (Figure 5). During the following
5 min washout period, LVDP returned to the pre-treatment value. HR was insignificantly
changed during perfusion of the hearts with 8-Br. RPP increased during the heart perfusion
with 8-Br to the maximum of 258 ± 28% and recovered to the pre-treatment level at the
end of the washout period (Figure 5).
3.2.2. Changes in Haemodynamic Function during Regional Ischaemia and Reperfusion
In the second series of experiments, changes in the haemodynamic function during
regional ischaemia in the C-Post and 8-Br-Post groups followed the pattern of the C-Pre
group. From the onset of ischaemia, LVDP fell immediately to 59 ± 5% and 69 ± 9%
in C- Post and 8-Br-Post groups, accordingly, and then started gradual recovery until
reperfusion in C-Post hearts, or the start of 8-Br perfusion in the 8-Br-Post group. The
recovery continued during reperfusion. In C-Post hearts, LVDP reached a maximum of
89 ± 8% on the 50th min of reperfusion. In 8-Br-Post hearts, LVDP recovered faster and
continued for longer, similar to the 8-Br-Pre group. This parameter significantly exceeded
the values of the C-Post group on the 30th, 60th and 120th min of reperfusion (Figure 6).
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HR did not change significantly over the regional ischaemia and reperfusion in both
groups of hear s. Therefore, the changes in RPP were simila to those of LVDP. RPP was
considerably higher in the 8-Br-Post group compared to control on the 60th and 120th min
of reperfusion (Figure 6).
3.2.3. Effect of 8-Br on Ventricular Arrhythmias during I/R
In the first series of experiments, where the hearts were treated with 8-Br prior to
regio al ischaemia, the number of i cidences of VPBs and VT/VF we e con iderably
smaller in 8-Br-Pre arts. The differences in the number of VT/VF and the arrhythmia
score, which combines the number of VPBs and tachyarrhythmias (VT and VF), were
significantly lower in 8-Br-Pre hearts compared to the C-Pre group both during ischaemia
and reperfusion (Table 1).
Table 1. Effects of 8-Br on ventricular arrhyth ias during regional ischae ia and reperfusion.
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Number of VPBs 409 ± 117 160 ± 62 211 ± 77 249 ± 62
Number of VT/VF 10 ± 2 3 ± 1 * 9 ± 2 3 ± 1 *
Arrhythmia Score 6.3 ± 0.2 4.8 ± 0.4* 6.4 ± 0.3 4.7 ± 0.6 *
8-Br-Pre—a group of hearts treated with 10 µM 8-Br at the end of preischaemia. 8-Br-Post—a group of hearts treated with 10 µM 8-Br at the
end of regional ischaemia. C-Pre and C-Post—control groups of hearts corresponding to 8-Br-Pre and 8-Br-Post. The data are presented as
the mean ± SEM. * p < 0.05 vs. control (C-Pre or C-Post, respectively).
In the second series of experiments, during ischaemia, when no heart was subjected
to 8-Br treatment, the parameters of ventricular arrhythmias were similar in the C-Post
and 8-Br-Post groups. However, perfusion of hearts with 8-Br by the onset of reperfusion
significantly reduced the number of incidences of VT/VF and the arrhythmia score during
reperfusion (Table 1).
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3.2.4. Cardiac Injury
The improved cardiac function recovery and reduced ventricular arrhythmias during
regional ischaemia and reperfusion in hearts treated with 8-Br were also accompanied by a
significant decrease in cardiac injury assessed by infarct size. Perfusion of hearts with 8-Br
by the start of regional ischaemia (8-Br-Pre group) reduced the infarct size-to-area-at-risk
ratio (AS/AAR) compared to control (C-Pre group) by 2.5-fold. When the hearts were
perfused with 8-Br at the onset of reperfusion (8-Br-Post group), the AS/AAR ratio fell by
3-fold compared to C-Post hearts (Figure 7).
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Figure . Infarct size in hearts of the first and second series of experiments. (A) First series of
experiments. The hearts were treated with 8 Br prior to regional ischaemia (8-Br-Pre group) or no
treatment with 8-Br (C-Pre group). (B) Second series of experiments. The hearts were treated with
8-Br at the end of regional ischaemia (8-Br-Post group) or received no treatment (C-Pre group). The
data are presented as the mean ± SEM. * p < 0.05 vs. 8-Br-Pre or 8-Br-Post group, respectively.
Representative images of the stained heart slices of each group are shown under the corresponding
bars. The red area, not stained ith Evance blue, is the area at risk. The dark-blue area is non-
isch emic myocardium, and the white, pale zone inside the area at risk is the infarcted (necrotic) area.
3.3. Ca2+-Induced Mitochondria Swelling
Perfusion of hearts with 8-Br following the equilibration period with no ischaemia
(8-Br-Mito group) significantly increased resistance of the mitochondria to elevated Ca2+
concentration manifested in reduced maximal rate and amplitude of mitochondria swelling
in these hearts by 2.5-fold (Figure 8).
3.4. Hexokinase II Binding to Mitochondria
The relative expression of HKII bound to mitochondria significantly increased in
hearts perfused with 8-Br at the end of the equilibration period (Figure 9).
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4. Discussion
In the experiments on isolated rat hearts, we recently found that the cell-permeable
non-selective cAMP analogue 8-Br, which activates the two main cAMP-related signalling
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pathways, PKA and Epac, can offer a strong cardioprotective effect when applied prior
to global ischaemia [16]. These finding, however, are applicable only to cardiac surgery
involving aortic cross-clamping, where the onset of an ischaemic event is predictable.
Meanwhile, patients often arrive at the hospital with already established AMI caused by
regional ischaemia, and the procedure of recanalization of the coronary artery may result
in irreversible damage to the myocardium caused by reperfusion [31]. This study shows
that brief perfusion of isolated rat hearts with 8-Br is able to protect them against regional
ischaemia. Importantly, this cAMP analogue can induce a protective effect when applied
not only before ischaemia but also by the onset of reperfusion. Our study also revealed that
these effects of 8-Br were likely related to an immediate inhibition of the MPTP mediated
by the binding of HKII to the mitochondrial membrane.
4.1. 8-Br Protects the Heart against Regional Ischaemia when Applied Either before Ischaemia or by
the Onset of Reperfusion
Perfusion of hearts with 8-Br before the start of LAD occlusion induced the protective
effect both during regional ischaemia and reperfusion. This was manifested in the improved
haemodynamic function, reduced ventricular arrhythmias, and significantly attenuated
infarct size (IS/AAR ratio) measured after 2 h of reperfusion.
The cardioprotective effect of the cAMP analogue 8-Br applied by the start of regional
ischaemia or reperfusion may seem surprising, since it has been found that stimulation of
β-adrenergic receptors (βARs) promotes cardiac arrhythmias through increased levels of
cAMP, activation of PKA and Epac [32,33]. Thus, it has been shown that the cardiotonic
drug milrinone, which inhibits the phosphodiesterase 3 (PDE3) family to improve cardiac
function by elevating cAMP, promotes sudden cardiac death due to arrhythmias [34].
PDE4 downregulation has been shown to enhance aberrant spontaneous pro-arrhythmic
release of Ca2+ [35,36]. Bobin et al. [37] have also found that β-adrenergic stimulation
by inhibition of PDE4 incurs positive inotropic effects, but these effects are associated
with the increased sarcoplasmic reticulum Ca2+ load and leak, resulting in the increased
occurrence of proarrhythmic spontaneous Ca2+ waves via cAMP-dependent PKA and Epac
pathways. Fazal et al. have shown that in failing human hearts, characterised by chronic
stimulation of β-adrenergic receptors, the expression of Epac1 is increased [38]. Further, the
authors used mice with genetic deletion of Epac1 to show that chronic inhibition of Epac1
activity is cardioprotective. The deleterious effects of Epac1, particularly mitochondrial
Epac1, were explained by Ca2+ overload and opening of the MPTP. Laudette et al. in their
review have also discussed the deleterious effects of Epac in cardiovascular and pulmonary
systems, and these effects were associated with chronic stimulation of cAMP signalling
pathways in conditions like myocardial remodelling, heart failure, and chronic obstructive
pulmonary disease. However, the modality of the effects of cAMP signalling depends on
several factors such as the timing, duration and dose of the treatment as well as the balance
between activation of Epac- and PKA-related pathways [16]. In particular conditions, an
increased level of cAMP is cardioprotective, and one of the manifestations of this effect
can be a reduction in cardiac arrhythmias. It is well known that ischaemic preconditioning
(IP) [39–41] and temperature preconditioning [42] prevent cardiac arrhythmias and this
effect is associated with elevated cAMP levels and PKA activation [19,43,44]. Furthermore,
previous studies of Lochner et al. [9] showed that activation of PKA by stimulation of βAR
triggers a protective effect similar to that of IP.
One of the possible explanations of the antiarrhythmic effects of IP is attenuation of
free cytosolic Ca2+ during prolonged ischemia due to the reduced ryanodine-dependent
release of Ca2+ from the sarcoplasmic reticulum [45], and by inhibited Ca2+ influx, efflux or
redistribution [46]. These effects are, in fact, opposite to the proarrhythmic effects of cAMP
signalling described above. This seeming controversy can be explained by the timing
and short duration of the cardioprotective intervention that stimulates cAMP signalling.
Apparently, a short (5 min) washout period, or its absence, determines the impact of the
elevated cAMP on the myocardial injury during I/R. Thus, Salie et al. [47] have recently
shown in experiments on isolated rat heart that during the 5 min washout period after
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IP induced by a 5 min global ischaemia, activation of the cell survival kinases, such as
p38MAPK, JNKp54/p46, Akt and extracellular signal-regulated kinase (ERK), takes place
that might determine the cardioprotective effect of PKA. Others have suggested that the
cAMP-dependent antiarrhythmic effect of IP is mediated by enhancing vagal influences [41].
The latter hypothesis is consistent with the fact that LVDP and RPP at the end of the washout
period in the 8-Br-Pre group of hearts fell below the pre-treatment values. Also, HR in
8-Br-Pre hearts was significantly elevated over the pre-treatment level on the 4th min
of the washout period but fell to the pre-treatment value on the 5th min (Figure 3). It
can be suggested that the brief perfusion of the heart with 8-Br leads to activation of the
intramural parasympathetic ganglia, which remain intact in a Langendorff-perfused rat
heart, resulting in the release of acetylcholine in the ventricles and induction of protection in
the ventricles by activation of muscarinic receptors, as it has been found for hearts subjected
to IP [48]. In 8-Br-Post hearts, haemodynamic function returned to the pre-treatment values
but did not fall further. This, however, does not exclude the possibility of intramural
parasympathetic ganglia activation, because the haemodynamic effects of this activation
could be hidden by the βAR activation taking place during ischaemia [49]. Earlier studies
have shown that cytoprotective effects of stimulation of these receptors could be mediated
by increased activities of anti-apoptotic enzymes Bcl-2, ERK and superoxide dismutase,
decreasing the pro-apoptotic mediators Fas and p38 [50]. Other possible mechanisms
of cardioprotection associated with the cAMP signalling may involve the opioidergic
system [51], prostanoids [52], nitric oxide [53], PKCε [16] or adenosine [54]. However,
further studies are needed to investigate the involvement of these suggested signalling
molecules and pathways in the cardioprotective effect of 8-Br.
We [18] and others [55–57] have found that MPTP opening is a core factor of reper-
fusion heart injury. Opening of this non-selective pore at the onset of reperfusion for a
relatively long period of time leads to breakdown of the electron transport chain, ROS
production, rupture of mitochondrial membranes, release, and activation of the proapop-
totic, necrotic and proinflammatory factors, and ultimately, irreversible damage to the
myocardium. Therefore, inhibition of MPTP represents an important mechanism of car-
dioprotection [58,59], and our finding of the ability of 8-Br to inhibit this pore is one of the
major results of this study.
4.2. Perfusion of Hearts with 8-Br Inhibits MPTP
The results of this work show that perfusion of hearts with 8-Br led to an immediate
increase in binding of HKII to mitochondria and inhibition of Ca2+-induced mitochondria
swelling, a well-established marker of the resistance of MPTP to Ca2+ overload [60]. The
binding of HKII to the outer mitochondrial membrane (OMM) has been linked to inhibition
of MPTP and anti-apoptotic effects [61,62], and it is negatively correlated to the extent
of ischaemia and infarct size [26]. Increased binding of HKII can be associated with
decreasing levels of glycogen, which results in a reduction in acidification and tissue
glucose-6-phosphate (G6P) levels that hamper HKII dissociation from mitochondria [26].
Although we did not measure the levels of glycogen and G6P in our study, the increase in
LVDP and RPP by 2–2.5-fold during the heart perfusion with 8-Br, either before or during
the regional ischaemia, might lead to glycogen depletion in the myocardium and promote
binding of HKII to the outer mitochondrial membrane. These results are consistent with
our previous study on isolated rat hearts showing that isoproterenol (or isoprenaline),
which activates cAMP signalling through stimulation of βARs, reduces glycogen content
in the myocardium and promotes binding of HKII to mitochondria [11]. Of note, this work
showed that stimulation of βARs by isoproterenol only induced a mild protective effect.
Our recent study has revealed that the optimal cardioprotective effect of the elevated levels
of cAMP signalling can be achieved as a result of simultaneous activation of its two main
downstream targets, PKA and Epac [16]. Meanwhile, Purves et al. found that PKA is
more sensitive to small elevations in cAMP, while Epac needs higher levels of cAMP for
its activation [63]. This is consistent with the finding that PKA is more sensitive to cAMP
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than Epac [64]. In contrast, Dao et al. found that cAMP displays a similar affinity to PKA
I and Epac1, and both PKA and Epac can react to similar physiological concentrations
of cAMP [65]. However, which of these proteins are preferentially activated by cAMP
depends not only on the affinity but also on the proximity of PKA and Epac to cellular
compartments with elevated levels of cAMP (e.g., βAR) [66]. It can be speculated that βAR
stimulation by isoproterenol results in preferential activation of PKA, either due to the
different sensitivities or closer proximity to βAR, whilst direct administration of the cell-
permeable cAMP analogue 8-Br results in a more equal activation of these two enzymes.
It should be also taken into account that isoproterenol is a non-selective βAR agonist
which can activate any type of βARs. However, in contrast to βAR1, which acts through
translocation of Gs protein and activation of the adenylate cyclase with the formation of
cAMP [67], βAR2 may activate Gi protein, and, thus, attenuate the effects of cAMP via
activation of guanylyl cyclase [68]. Thus, the difference in the cardioprotective efficacy
between 8-Br and isoproterenol could be associated with either an insufficient activation
of Epac by the βAR stimulation with isoproterenol or/and with a possible inhibition of
the cAMP signalling through activation of Gi protein when stimulation of the βARs by
isoproterenol is relatively high.
The binding of HKII to the OMM plays both metabolic and membrane-stabilising
roles. Thus, it has been shown that the increased cytochrome c release, ROS production,
and infarct size on reperfusion in hearts with depleted mitochondria-bound HKII was
associated with the opening of the MPTP, and increased permeabilization of the OMM with
degradation of Bcl-xL [26]. Others have found that HKII bound to OMM prevents binding
of the pro-apoptotic enzyme BAX to mitochondria, which also prevents cytochrome c
release from the mitochondria [69]. The enzymatic effects of increased HKII binding to
OMM are manifested in the prevention of acidosis via the enhanced coupling of glycolysis
and glucose oxidation and inhibition of fatty acid oxidation. This metabolic function of the
mitochondria-bound HKII also results in inhibition of ROS production [70,71]. Therefore,
the enzyme activity of HKII in the membrane-bound state has its own protective value,
which needs to be further investigated in relation to the cardioprotective effects of 8-
Br. Using an inhibitor of HKII, such as 3-bromo pyruvate, could help to differentiate the
protective role of HKII associated with the enzymatic activity from its membrane-stabilising
function. However, for these experiments, the enzymatic activity needs to be inhibited in
the membrane-bound but not in the dissolved state of HKII.
It is important to stress that we perfused the hearts with 8-Br at the end of regional
ischaemia in order to ensure that the drug affects the MPTP at the very beginning of
reperfusion because the opening of this pore is observed during the first minutes of
reperfusion [72]. Importantly, we found that 8-Br immediately promotes binding of HKII
to mitochondria and inhibits MPTP (reduces Ca2+-induced mitochondria swelling), which
is critical for salvaging the myocardium in these conditions. Considering the importance
of MPTP opening for reperfusion injury, we may suggest that this effect is a key factor of
the cardioprotective effect of 8-Br applied at the onset of reperfusion. However, a recent
work of Pereira et al. has demonstrated that in vitro dissociation of HKII alone does not
fully replicate the effects of global ischaemia on mitochondrial function [73]. The authors
concluded that in vivo dissociation of HKII regulates mitochondrial function at the end of
ischaemia indirectly, probably by interaction with mitochondrial fission proteins such as
Drp1 and Drp2. They hypothesised that the changes in cristae structure and mitochondrial
morphology occurred due to this interaction destabilised the integration between the outer
and inner membrane, resulting in increased cytochrome c release and sensitising MPTP to
Ca2+ overload.
It should be noted that our studies were performed on healthy mitochondria. In dis-
eased conditions, the reaction of mitochondria to 8-Br treatment could differ from healthy
mitochondria. In the future, the effect of 8-Br on the binding of HKII to mitochondria
and MPTP opening can be tested in more clinically relevant diseased models (e.g., heart
failure following coronary artery occlusion) where the isolated mitochondria will come
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from a diseased heart. Also, these measurements need to be accompanied by evaluation
of cytochrome c release from mitochondria and activation of caspase cascade leading to
apoptosis. However, we would like to point out that the protective effect manifested in the
reduction of cardiac arrhythmias, infarct size, and the improved haemodynamic function
was observed in hearts treated with 8-Br not only before but also at the end of regional
ischaemia, indicating the potential of 8-Br to protect the heart in a pathological state. The
distribution of 8-Br over the ischaemic and non-ischaemic areas during the coronary artery
occlusion and the reaction of these mitochondria to the treatment with 8-Br need to be
studied in future experiments.
It needs to be taken into account that the results obtained in experiments on small
rodents, including those on the pathological models, cannot be directly extrapolated to
humans [74]. To advance the translation of these results to clinical practice, the protective
effects of 8-Br need to be tested on a large animal model, such as a pig, in which morpho-
logical and physiological characteristics of the cardiovascular system are closely matched
to humans [75]. Over the years, we have developed expertise in porcine models of cardiac
surgery with cardio-pulmonary bypass and cardioplegic arrest [76,77]. This experience can
be employed should the experiments on pathological in vivo and ex vivo models in rats
confirm the potent cardioprotective effect of 8-Br.
Taken together, the results of this study show for the first time that the cell-permeable
cAMP analogue 8-Br is able to protect the heart against regional ischaemia/reperfusion
injury when applied either before ischaemia or by the onset of reperfusion. These find-
ings widen the clinical relevance of 8-Br as a potential drug for the prevention of is-
chaemia/reperfusion injury occurring during the coronary recanalization procedure in
AMI patients as well as in heart surgery involving aortic cross-clumping. Immediate
binding of HKII to mitochondria and inhibition of MPTP are likely mechanisms underlying
this protective effect.
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